Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.

Basic Information

ID: ALA1833834

Journal: Bioorg Med Chem Lett

Title: Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.

Authors: Yu D, Sakurai F, Corey DR.

Abstract: Rett Syndrome is an X-linked progressive neurological disorder caused by inactivation of one allele of the MECP2 gene. There are no curative treatments, and activation of wild-type MECP2 expression is one strategy for stabilizing or reversing the disease. We isolated fibroblast clones that express exclusively either the wild-type or a 32-bp-deletion mutant form of MECP2. We developed a sensitive assay for measuring wild-type MECP2 mRNA levels and tested small molecule epigenetic activators for their ability to activate gene expression. Although our pilot screen did not identify activators of MECP2 expression, it established the value of using clonal cells and defined challenges that must be overcome.

CiteXplore: 21840716

DOI: 10.1016/j.bmcl.2011.07.053

Patent ID: ┄